Open AccessTargeting host nucleotide biosynthesis with resveratrol inhibits emtricitabine-resistant HIV-1
Author(s) -
Alonso Heredia,
Charles E. Davis,
Md. Ruhul Amin,
Nhut Le,
Mark A. Wainberg,
Maureen Oliveira,
Steven G. Deeks,
Lai-Xi Wang,
Robert Redfield
Publication year - 2014
Publication title -
aids
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0000000000000168
Subject(s) - resistance mutation , reverse transcriptase , biology , resveratrol , mutant , microbiology and biotechnology , virology , biochemistry , gene , rna
The M184V mutation in the HIV-1 reverse transcriptase gene is frequent (>50%) in patients, both in resource-rich and resource-limited countries, conferring high-level resistance (>100-fold) to the cytosine analog reverse transcriptase inhibitors lamivudine and emtricitabine. The reverse transcriptase enzyme of M184V HIV-1 mutants has reduced processivity, resulting in reduced viral replication, particularly at low deoxynucleotide (dNTP) levels. We hypothesized that lowering intracellular dNTPs with resveratrol, a dietary supplement, could interfere with replication of M184V HIV-1 mutants.